Heart inflammation rates higher after Moderna COVID-19 vaccine: Canada data

Moderna Covid-19 Vaccine


Canadian health officials said on Friday data suggests reported cases of rare heart inflammation were relatively higher after Moderna’s COVID-19 vaccine compared with the Pfizer/BioNTech shots.

The data also indicated heart inflammation occurs more often in adolescents and adults under 30 years of age, and more often in males.

The statement from the Public Health Agency of Canada said majority of the affected individuals experienced relatively mild illness and recovered quickly.

The risk of cardiac complications, including heart inflammation, has been shown to be substantially increased following COVID-19 infections, with the risks higher after the infection than after vaccination, according to the statement.

The benefits of mRNA shots in preventing COVID-19 continue to outweigh the risks, regulators in the United States, EU and the World Health Organization have said.

Source: Tech Crunch

You can message yourself on WhatsApp to take notes

whatsapp take notes,whatsapp new feature

The popular instant messaging app WhatsApp has a feature that you can use to message on your own number to add notes or save some important information.

The “click to chat” feature allows you to start a chat with someone without having their phone number saved in your phone’s address book.

Here’s how you can message yourself:

  • First, you are required to open any browser on your phone. Make sure that you are connected to the internet.
  • Now, you need to copy this “wa.me//” in the address bar and add your WhatsApp phone number after that. You will also have to add your country code before entering mobile number because if you don’t do that the app will term your number invalid. For example, the Pakistani users need to type “wa.me//92XXXXXXXXXx.
  • You will now be redirected to a WhatsApp page. You will be able to see your phone number on the top and a box that reads, “Continue to Chat”. Click on that box.
  • Your chat window will be visible along with all your chats. Now, you can start messaging on your number and add notes.

It is noteworthy that the process is similar for both mobile and web versions

You can follow the same process to chat with an unknown person without saving their number.

Source: Tech Crunch

How to use WhatsApp dark mode on Android, iOS and desktop

Have your eyes thanking you by knowing how to use WhatsApp dark mode when you’re chatting away late at night.

A new WhatsApp feature makes the app easier to see in poorly lit surroundings, and knowing how to switch on dark mode can help prevent you from having to strain your eyes.

Considering that the WhatsApp is currently one of the most used apps around, this should help serial-texters a great deal.

Below is the step-by-step guide to the entire process on how to use WhatsApp dark mode on Android, iOS and desktop.

How to use WhatsApp dark mode on Android

Tap the three dots in the upper-right corner of your screen.

Tap on Settings

Tap the Chats option as seen below.

Go to Themes located at the top

Go in the ‘Choose theme’ window and toggle the ‘Dark’ setting.

Yeap, you’ve now activated WhatsApp dark mode.

How to do the same on iPhone
Unfortunately, on iOS devices it’s not possible to simply switch on dark mode for WhatsApp exclusively. But there’s a way around via iPhone’s default settings to dark mode, WhatsApp will follow suit.

Gyour iPhone’s Settings app.

Select the “Display & Brightness” option

Now toggle the Dark appearance setting

Now you’ve now activated your iPhone’s dark mode which would work for WhatsApp as well.

How to do the same on desktop

Go the three dots located just above your chat logs.

Select the Settings option in the drop-down menu

Go to the option titled “Theme.”

Toggle here the “Dark” bubble and click on OK

WhatsApp dark mode on your desktop activated.

Facebook Notice for EU! You need to login to view and post FB Comments!

The post How to use WhatsApp dark mode on Android, iOS and desktop appeared first on ARY NEWS.

from ScienceTechnology – ARY NEWS https://ift.tt/3D2Ly13 https://ift.tt/3oq7D5O
Source: Tech Crunch

iPhone 13 Diary: Quick Cinematic Video tests excite me

I’ve so far only done a handful of quick Cinematic Video tests on my iPhone 13 Pro Max following my earlier macro photography tests. While the results haven’t been perfect, they have certainly been good enough to show the potential of the technology.

In particular, the ability to adjust the focus points in editing makes it an extremely powerful tool. Honestly, for manual mode in particular, I’m excited…

more…

The post iPhone 13 Diary: Quick Cinematic Video tests excite me appeared first on 9to5Mac.

from 9to5Mac https://ift.tt/39YojbY https://ift.tt/3B0gEpr
Source: Tech Crunch

Take a look inside your iPhone 13 Pro with these X-ray and teardown wallpapers from iFixit

After completing teardown of the new iPhone 13 lineup, iFixit has now shared some neat teardown and X-ray wallpapers that offer a look inside Apple’s latest flagship. These are fun wallpapers that make it seem like your iPhone 13 Pro or iPhone 13 Pro Max is see-through…

more…

The post Take a look inside your iPhone 13 Pro with these X-ray and teardown wallpapers from iFixit appeared first on 9to5Mac.

from 9to5Mac https://ift.tt/3onKGjs https://ift.tt/3kWzoki
Source: Tech Crunch

Merck’s COVID-19 pill cuts risk of death, hospitalization by 50%: study

Merck’s COVID-19


Merck’s experimental oral drug for COVID-19, molnupiravir, reduced by around 50% the chance of hospitalization or death for patients at risk of severe disease, according to interim clinical trial results announced on Friday.

Merck and partner Ridgeback Biotherapeutics plan to seek U.S. emergency use authorization for the pill as soon as possible, and to submit applications to regulatory agencies worldwide. Due to the positive results, the Phase 3 trial is being stopped early at the recommendation of outside monitors.

“This is going to change the dialog around how to manage COVID-19,” Robert Davis, Merck’s chief executive officer, told Reuters.

If authorized, molnupiravir, which is designed to introduce errors into the genetic code of the virus, would be the first oral antiviral medication for COVID-19.

Rivals including Pfizer Inc and Swiss pharmaceutical Roche Holding AG are racing to develop an easy-to-administer antiviral pill for COVID-19 but so far, only antibody cocktails – which have to be given intravenously – are approved for treating non-hospitalized COVID-19 patients.

A planned interim analysis of 775 patients in Merck’s study found that 7.3% of those given molnupiravir were either hospitalized or had died by 29 days after treatment, compared with 14.1% of placebo patients. There were no deaths in the molnupiravir group, but there were eight deaths of placebo patients.

“Antiviral treatments that can be taken at home to keep people with COVID-19 out of the hospital are critically needed,” Wendy Holman, Ridgeback’s CEO, said in a statement.

In the trial, which enrolled patients around the world, molnupiravir was taken every 12 hours for five days.

The study enrolled patients with laboratory-confirmed mild-to-moderate COVID-19, who had symptoms for no more than five days. All patients had at least one risk factor associated with poor disease outcome, such as obesity or older age.

Merck said viral sequencing done so far shows molnupiravir is effective against all variants of the coronavirus, including highly transmissible Delta.

The company said rates of adverse events were similar for both molnupiravir and placebo patients, but did not give details of the side effects.

Merck has said data shows molnupiravir is not capable of inducing genetic changes in human cells, but men enrolled in its trials have to abstain from heterosexual intercourse or agree to use contraception. Women of child-bearing age cannot be pregnant and also have to use birth control.

Merck said it expects to produce 10 million courses of the treatment by the end of 2021, with more doses coming next year.

The company has a U.S. government contract to supply 1.7 million courses of molnupiravir at a price of $700 per course.

CEO Davis said Merck has similar agreements with other governments worldwide, and is in talks with more. The company said it plans to implement a tiered pricing approach based on country income criteria.

Merck has also agreed to license the drug to several India-based generic drugmakers, which would be able to supply the treatment to low- and middle-income countries.

Molnupiravir is also being studied in a Phase 3 trial for preventing coronavirus infection in people exposed to the virus.

Merck officials said it is unclear how long the FDA review of the drug will take.

“I believe that they are going to try to work with alacrity on this,” said Dean Li, head of Merck’s research labs.

Source: Tech Crunch